Highest-materiality recent filing
Bio Essence acquires MediFlow AI software for $3.5M in restricted stock
Bio Essence (BIOE) entered an Asset Purchase Agreement to buy the MediFlow AI (formerly AcuVital) platform from Zhituo Software.
Bio Essence Corp. restates Q1 2024 financials due to unapproved lease termination accounting error
Determined on Aug 19, 2024 that financial statements for Q1 ended March 31, 2024 cannot be relied upon.
Bio Essence Corp. converts $2.5M CEO debt into 5M shares
Board approved conversion of $2,500,000 debt owed to CEO Yin Yan into 5,000,000 common shares.
On June 12, 2024, Yangyang Huang and Simon Shavanson (collectively the “Resigning Directors”) resigned from the Board of Directors of Bio Essence Corp. (the “Company”).
On June 18, 2024, the Company’s remaining directors unanimously appointed William Sluss to the Board of Directors pursuant to Article II, Section 6 of the Company’s Bylaws.
On June 12, 2024, Yangyang Huang and Simon Shavanson (collectively the “Resigning Directors”) resigned from the Board of Directors of Bio Essence Corp. (the “Company”).
On December 8, 2023, the Company received notice from Sharon Mair, a member of the Company’s Board of Directors, that she resigned from the Board of Directors effective immediately.
On September 7, 2023, William E. Sluss was appointed as Chief Financial Officer (Principal Financial Officer) of Bio Essence Corp. (the “Company”).
Max materiality 0.75 · Median 0.50 · Most common event m_and_a